A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer (NCT06693687)
🩺 Plain-English Summary (8th-Grade Level)
To evaluate the rate of therapy discontinuation due to toxicity (side effects) among participants with cancer using ApricityCare. Investigators want to learn if identification of early clinical signs of irAEs with timely treatment can prevent severity progression and reduce treatment discontinuation.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (1 items).
Location: MD Anderson Cancer Center — Houston, Texas
Age range: 18 Years
🧪 Interventions in This Study
- Metastatic Cancer (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria: \- Have any medical, psychological, or social condition that, in the opinion of the investigator would preclude participation in this study (pregnancy is not exclusionary and pregnant women will be permitted to enroll in the study).
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- MD Anderson Cancer Center — Houston, Texas
📞 Contact the Study Coordinator
Phone: (713) 563-4600
Email: basiddiqui@mdanderson.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Cancer
- A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors — Hartford, Connecticut
- Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers — Chicago, Illinois
- Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. — Los Angeles, California
- Biomarkers to Detect Endocrine Therapy Resistance — Madison, Wisconsin
- Niraparib in Tumors Metastatic to the CNS — Boston, Massachusetts
Explore by condition: All Metastatic Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.